Joanna Hauser
A5002092788- Bipolar Disorder and Treatment
- Genetic Associations and Epidemiology
- Genetics and Neurodevelopmental Disorders
- Tryptophan and brain disorders
- Treatment of Major Depression
- Genetic Syndromes and Imprinting
- Eating Disorders and Behaviors
- Autism Spectrum Disorder Research
- Stress Responses and Cortisol
- Mental Health Research Topics
- Adolescent and Pediatric Healthcare
- Pharmacogenetics and Drug Metabolism
- Diet and metabolism studies
- Neurotransmitter Receptor Influence on Behavior
- Child and Adolescent Psychosocial and Emotional Development
- Nerve injury and regeneration
- Attention Deficit Hyperactivity Disorder
- Suicide and Self-Harm Studies
- Hormonal Regulation and Hypertension
- Schizophrenia research and treatment
- Digestive system and related health
- Receptor Mechanisms and Signaling
- Nuclear Receptors and Signaling
- Asthma and respiratory diseases
- Cognitive Abilities and Testing
Poznan University of Medical Sciences
2016-2025
University of Utah
2023
Virginia Commonwealth University
2019-2023
Huntsman (United States)
2023
Universitäre Psychiatrische Kliniken Basel
2023
Genomics (United Kingdom)
2017-2022
Duke University Health System
2022
Massachusetts General Hospital
2010-2019
Icahn School of Medicine at Mount Sinai
2019
State University of New York
2019
Objective The assessment of response to lithium maintenance treatment in bipolar disorder (BD) is complicated by variable length treatment, unpredictable clinical course, and often inconsistent compliance. Prospective retrospective methods have been proposed the literature. In this study we report key phenotypic measures “Retrospective Criteria Long-Term Treatment Response Research Subjects with Bipolar Disorder” scale currently used Consortium on Lithium Genetics (ConLiGen) study. Materials...
Objective: Major depressive disorder has been linked with inflammatory processes, but it is unclear whether individual differences in levels of biomarkers could help match patients to treatments that are most likely be beneficial. The authors tested the hypothesis C-reactive protein (CRP), a commonly available marker systemic inflammation, predicts differential response escitalopram (a serotonin reuptake inhibitor) and nortriptyline norepinephrine inhibitor). Method: was Genome-Based...
Background Symptom dimensions have not yet been comprehensively tested as predictors of the substantial heterogeneity in outcomes antidepressant treatment major depressive disorder. Method We nine symptom derived from a previously published factor analysis depression rating scales outcome 811 adults with moderate to severe treated flexibly dosed escitalopram or nortriptyline Genome-based Therapeutic Drugs for Depression (GENDEP). The effects were mixed-effect regression models that...
Objective The purpose of this study was to identify genetic variants underlying the considerable individual differences in response antidepressant treatment. authors performed a genome-wide association analysis improvement depression severity with two drugs. Method High-quality Illumina Human610-quad chip genotyping data were available for 706 unrelated participants European ancestry treated major escitalopram (N=394) or nortriptyline (N=312) over 12-week period Genome-Based Therapeutic...
Abstract Borderline personality disorder (BOR) is determined by environmental and genetic factors, characterized affective instability impulsivity, diagnostic symptoms also observed in manic phases of bipolar (BIP). Up to 20% BIP patients show comorbidity with BOR. This report describes the first case–control genome-wide association study (GWAS) BOR, performed one largest BOR patient samples worldwide. The focus our analysis was (i) detect genes gene sets involved (ii) investigate overlap...
The outcome of treatment with antidepressants varies markedly across people the same diagnosis. A clinically significant prediction outcomes could spare frustration trial and error approach improve major depressive disorder through individualized selection. It is likely that a combination multiple predictors needed to achieve such prediction. We used elastic net regularized regression optimize symptom improvement remission during escitalopram or nortriptyline identify contributing from range...
A number of scales are used to estimate the severity depression. However, differences between self-report and clinician rating, multi-dimensionality different weighting individual symptoms in summed scores may affect validity measurement. In this study we examined integrated psychometric properties three commonly rating scales.The 17-item Hamilton Depression Rating Scale (HAMD-17), Montgomery-Asberg (MADRS) Beck Inventory (BDI) were administered 660 adult patients with unipolar depression a...
Background Adverse drug reactions are important determinants of non-adherence to antidepressant treatment but their assessment is complicated by overlap with depressive symptoms and lack reliable self-report measures. Aims To evaluate a simple measure describe adverse antidepressants in large sample. Method The newly developed Antidepressant Side-Effect Checklist the psychiatrist-rated UKU Side Effect Rating Scale were repeatedly administered 811 adult participants depression part-randomised...
Background Tricyclic antidepressants and serotonin reuptake inhibitors are considered to be equally effective, but differences may have been obscured by internally inconsistent measurement scales inefficient statistical analyses. Aims To test the hypothesis that escitalopram nortriptyline differ in their effects on observed mood, cognitive neurovegetative symptoms of depression. Method In a multicentre part-randomised open-label design (the Genome Based Therapeutic Drugs for Depression...
For more than half a decade, lithium has been successfully used to treat bipolar disorder. Worldwide, it is considered the first-line mood stabilizer. Apart from its proven antimanic and prophylactic effects, considerable evidence also suggests an antisuicidal effect in affective disorders. Lithium effectively augment antidepressant drugs treatment of refractory major depressive episodes prevent relapses recurrent unipolar depression. In contrast many psychiatric drugs, outlasted various...
Background There have been conflicting reports on whether the length polymorphism in promoter of serotonin transporter gene (5-HTTLPR) moderates antidepressant effects selective reuptake inhibitors (SSRIs). We hypothesised that pharmacogenetic effect 5-HTTLPR is modulated by gender, age and other variants gene. Aims To test hypothesis differently influences response to escitalopram (an SSRI) compared with nortriptyline (a noradrenaline inhibitor). Method The 13 additional markers across were...
<h3>Importance</h3> Lithium is a first-line mood stabilizer for the treatment of bipolar affective disorder (BPAD). However, efficacy lithium varies widely, with nonresponse rate up to 30%. Biological response markers are lacking. Genetic factors thought mediate lithium, and there previously reported genetic overlap between BPAD schizophrenia (SCZ). <h3>Objectives</h3> To test whether polygenic score SCZ associated in explore potential molecular underpinnings this association. <h3>Design,...